Is body posture relevant for neonatal studies?

P. Casaer,Y. Akiyama

Abstract:

What problem does this paper attempt to address?

Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies

Bing-Mae Chen,Tian-Lu Cheng,Steve R. Roffler

DOI: https://doi.org/10.1021/acsnano.1c05922

IF: 17.1

2021-09-01

ACS Nano

Abstract:Polyethylene glycol (PEG) is a flexible, hydrophilic simple polymer that is physically attached to peptides, proteins, nucleic acids, liposomes, and nanoparticles to reduce renal clearance, block antibody and protein binding sites, and enhance the half-life and efficacy of therapeutic molecules. Some naïve individuals have pre-existing antibodies that can bind to PEG, and some PEG-modified compounds induce additional antibodies against PEG, which can adversely impact drug efficacy and safety. Here we provide a framework to better understand PEG immunogenicity and how antibodies against PEG affect pegylated drug and nanoparticles. Analysis of published studies reveals rules for predicting accelerated blood clearance of pegylated medicine and therapeutic liposomes. Experimental studies of anti-PEG antibody binding to different forms, sizes, and immobilization states of PEG are also provided. The widespread use of SARS-CoV-2 RNA vaccines that incorporate PEG in lipid nanoparticles make understanding possible effects of anti-PEG antibodies on pegylated medicines even more critical.This article has not yet been cited by other publications.

materials science, multidisciplinary,chemistry, physical,nanoscience & nanotechnology
Hydroxy polyethylene glycol: a solution to evade human pre-existing anti-PEG antibodies for efficient delivery

Tianhao Ding,Jiaru Fu,Min Yang,Zui Zhang,Yinyu Ma,Ercan Wu,Zhiwei Guo,Shiqi Lin,Songli Wang,Xiaohua Liu,Bin Wang,Guanghui Li,Changyou Zhan

DOI: https://doi.org/10.1101/2024.10.21.619346

2024-10-24

Abstract:Polyethylene glycol (PEG) has been extensively utilized in food, cosmetics, and pharmaceutical fields, especially in the realm of nanomedicines, where it serves as a pivotal excipient for extending the nanoparticles circulation half-life. Contrary to its historical perception as non-immunogenic, pre-existing anti-PEG antibodies have been widely detected in human who even have never been exposed to PEGylated therapeutics, which considered to be associated with serious side effects of PEGylated nanomedicines including infusion reactions and other hypersensitive reactions. Herein, we elucidated the prevalence and distribution characteristics of pre-existing anti-PEG antibodies in 2074 human blood samples, and investigated its binding with PEG. Pre-existing anti-PEG antibodies were found to primarily recognize the PEG terminus, especially methoxy, which is the only PEG terminus contained in currently marketed PEGylated nanomedicines. While hydroxy PEG (OH-PEG) significantly evaded binding with pre-existing anti-PEG antibodies among most clinical samples. Noteworthily, substituting OH-PEG for MeO-PEG significantly mitigated complement activation of lipid nanoparticle (LNP) caused by pre-existing anti-PEG antibodies, thereby markedly enhancing stability and reducing mRNA leakage in human serum. Additionally, LNP modified with OH-PEG exhibited reduced immunogenicity, which was crucial for repeated drug administrations. The present work elucidated the crucial role of OH-PEG in evading human pre-existing anti-PEG antibodies, and discovered that the current pre-clinical studies inadequately simulated the biological effects of clinical pre-existing anti-PEG antibodies on such formulations through interspecies study, which had a profound impact on clinical translation of PEGylated nanomedicines.

Pharmacology and Toxicology
Anti-PEG Antibodies: Current Situation and Countermeasures

Jiaru Fu,Ercan Wu,Guanghui Li,Bin Wang,Changyou Zhan

DOI: https://doi.org/10.1016/j.nantod.2024.102163

IF: 17.4

2024-01-01

Nano Today

Abstract:Polyethylene glycol (PEG) is continuing to be a star molecular to increase hydrophilicity and to lengthen the blood circulation after conjugation with therapeutic proteins, nucleotides and nanocarriers. In contrary to the inherent idea, anti-PEG antibodies have been discovered in multiple species after treatment with PEGylated therapeutics. It is even worse that pre-existing anti-PEG antibodies demonstrate increasing prevalence in healthy people without prior exposure to PEGylated therapeutics but reasons underlying await to be clarified. Anti-PEG antibodies, no matter induced or pre-existing, would exert a series of biological effects including but not limited to accelerated blood clearance (ABC) phenomenon, and hypersensitivity reactions after encountering with PEGylated therapeutics, which potentially cause hazards to efficacy and safety of clinical medication. Considering the wide application of PEG in pharmaceutical field, mechanistic understanding on anti-PEG antibodies production and strategies to manage the consequent biological effects are desperately needed. In this review, the prevalence and possible mechanism of anti-PEG antibodies production were outlined. A series of factors that affecting our understanding the impacts of anti-PEG antibodies on in vivo biological effects against PEGylated therapeutics and potential countermeasures were highlighted.
PEGylated Liposomes for Diagnosis of Polyethylene Glycol Allergy

Griffith B. Perkins,Matthew J. Tunbridge,Plinio R. Hurtado,James Zuiani,Shweta Mhatre,Kwok Ho Yip,Thanh-Thao Adriana Le,Carlo Yuson,Frank Kette,Pravin Hissaria

DOI: https://doi.org/10.1016/j.jaci.2024.03.030

IF: 14.29

2024-05-09

Journal of Allergy and Clinical Immunology

Abstract:Background Polyethylene glycol (PEG) is a non-protein polymer that is present in its native (unbound) form as an excipient in a range of products, and is increasingly being utilised clinically in the form of PEGylated liposomal medications and vaccines. PEG is the cause of anaphylaxis in a small percentage of drug reactions, however diagnosis of PEG allergy is complicated by the variable and poor diagnostic performance of current skin testing protocols. Objective We assessed the diagnostic performance of PEGylated lipid medications as an alternative to currently described tests that use medications containing PEG excipients. Methods Nine patients with a strong history of PEG allergy were evaluated by skin testing with a panel of PEG-containing medications, and with a PEGylated lipid nanoparticle vaccine (BNT162b2). Reactivity of basophils to unbound and liposomal PEG was assessed ex vivo, and specificity of basophil responses to PEGylated liposomes was investigated with a competitive inhibition assay. For detailed Methods, please see the Methods section in this article's Online Repository. Results Despite compelling histories of anaphylaxis to PEG-containing medications, only two out of nine patients (22%) returned a positive skin test to purified PEG or their index-reaction indicated PEG-containing compound. Conversely, nine out of nine patients (100%) were skin test positive or basophil activation test positive to PEGylated liposomal BNT162b2 vaccine. Concordantly, PEGylated liposomal drugs (BNT162b2 vaccine and PEGylated liposomal doxorubicin), but not purified PEG2000, consistently induced basophil activation ex vivo in patients with PEG allergy but not in non-allergic controls. Basophil reactivity to PEGylated nanoparticles competitively inhibited by pre-incubation of basophils with native PEG2000. Conclusion We demonstrate that presentation of PEG on the surface of a lipid nanoparticle increases its in vivo and ex vivo allergenicity, and improves diagnosis of PEG allergy.

immunology,allergy
A singlicate immunogenicity method to detect anti-polyethylene glycol antibodies: pre- and post-dose of PEGylated therapies

Issa Jyamubandi,Aanya Aamir,Jyotsna Kaur,Alen Sylvester,Richard Hughes,Sophia Li

DOI: https://doi.org/10.4155/bio-2023-0196

IF: 2.695

2024-01-01

Bioanalysis

Abstract:Aim: Preexisting anti-polyethylene glycol (PEG) antibodies (APAs) may affect the efficacy and safety of PEGylated compounds. Omontys ® and Krystexxa ® withdrawal and SARS-CoV-2 RNA vaccine anaphylaxis have all been linked to APAs. This project aimed to develop and validate a method to detect total antibodies against PEG, pre- and post-dose. Materials & methods: The repetitive, linear PEG structure prevented the use of a bridging homogenous format, hence the requirement to use a solid-phase extraction and acid dissociation assay coupled with the Meso Scale Discovery ® platform. Results & conclusion: Using singlicate analysis, the method was validated to successfully detect APA pre- and post-dose, with a crucial aspect of the method being the preparation of an appropriate negative control.

biochemical research methods,chemistry, analytical
To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives

Da Shi,Damian Beasock,Adam Fessler,Janos Szebeni,Julia Y Ljubimova,Kirill A Afonin,Marina A Dobrovolskaia

DOI: https://doi.org/10.1016/j.addr.2021.114079

Abstract:Polyethylene glycol or PEG has a long history of use in medicine. Many conventional formulations utilize PEG as either an active ingredient or an excipient. PEG found its use in biotechnology therapeutics as a tool to slow down drug clearance and shield protein therapeutics from undesirable immunogenicity. Nanotechnology field applies PEG to create stealth drug carriers with prolonged circulation time and decreased recognition and clearance by the mononuclear phagocyte system (MPS). Most nanomedicines approved for clinical use and experimental nanotherapeutics contain PEG. Among the most recent successful examples are two mRNA-based COVID-19 vaccines that are delivered by PEGylated lipid nanoparticles. The breadth of PEG use in a wide variety of over the counter (OTC) medications as well as in drug products and vaccines stimulated research which uncovered that PEG is not as immunologically inert as it was initially expected. Herein, we review the current understanding of PEG's immunological properties and discuss them in the context of synthesis, biodistribution, safety, efficacy, and characterization of PEGylated nanomedicines. We also review the current knowledge about immunological compatibility of other polymers that are being actively investigated as PEG alternatives.
The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?

Christian Lubich,Peter Allacher,Maurus de la Rosa,Alexander Bauer,Thomas Prenninger,Frank Michael Horling,Jürgen Siekmann,Johannes Oldenburg,Friedrich Scheiflinger,Birgit Maria Reipert

DOI: https://doi.org/10.1007/s11095-016-1961-x

IF: 4.58

2016-06-07

Pharmaceutical Research

Abstract:PurposeRecent findings demonstrated anti-PEG antibody formation in some healthy individuals and patients who have not received PEGylated biotherapeutics. Some of these findings evoked criticism because of shortcomings in the antibody assays used. To better understand this topic, we established robust antibody analytics and screened two cohorts of healthy individuals and one cohort of hemophilia patients for the expression of anti-PEG antibodies.MethodsA flow cytometry approach and a fully validated ELISA platform were established to detect specific anti-PEG antibodies. Immunohistochemistry was used to test for potential binding of anti-PEG antibodies to human tissues.ResultsIgM and/or IgG anti-PEG antibodies are expressed by some healthy individuals and by some patients with hemophilia who have not received PEGylated biotherapeutics. These antibodies can be either transient or persistent and recognize PEGs of different sizes with or without terminal methoxy groups. Age and location of healthy individuals influence the prevalence of IgG but not of IgM antibodies. Anti-PEG antibodies do not cross-react with human tissues supporting the safety of the antibodies.ConclusionWe confirm that some healthy individuals and some patients with hemophilia express specific antibodies against PEG which are not associated with any pathology and do not bind to human tissues.

pharmacology & pharmacy,chemistry, multidisciplinary
Impact of Anti-PEG IgM Induced via the Topical Application of a Cosmetic Product Containing PEG Derivatives on the Antitumor Effects of PEGylated Liposomal Antitumor Drug Formulations in Mice

Sherif A Gaballa,Taro Shimizu,Haruka Takata,Hidenori Ando,Mohamed Ibrahim,Sherif E Emam,Nana Cristina Amorim Matsuo,Yuri Kim,Youssef W Naguib,Fatma M Mady,Khaled A Khaled,Tatsuhiro Ishida

DOI: https://doi.org/10.1021/acs.molpharmaceut.3c00774

2024-02-05

Abstract:Poly(ethylene glycol) (PEG) is used in many common products, such as cosmetics. PEG, however, is also used to covalently conjugate drug molecules, proteins, or nanocarriers, which is termed PEGylation, to serve as a shield against the natural immune system of the human body. Repeated administration of some PEGylated products, however, is known to induce anti-PEG antibodies. In addition, preexisting anti-PEG antibodies are now being detected in healthy individuals who have never received PEGylated therapeutics. Both treatment-induced and preexisting anti-PEG antibodies alter the pharmacokinetic properties, which can result in a subsequent reduction in the therapeutic efficacy of administered PEGylated therapeutics through the so-called accelerated blood clearance (ABC) phenomenon. Moreover, these anti-PEG antibodies are widely reported to be related to severe hypersensitivity reactions following the administration of PEGylated therapeutics, including COVID-19 vaccines. We recently reported that the topical application of a cosmetic product containing PEG derivatives induced anti-PEG immunoglobulin M (IgM) in a mouse model. Our finding indicates that the PEG derivatives in cosmetic products could be a major cause of the preexistence of anti-PEG antibodies in healthy individuals. In this study, therefore, the pharmacokinetics and therapeutic effects of Doxil (doxorubicin hydrochloride-loaded PEGylated liposomes) and oxaliplatin-loaded PEGylated liposomes (Liposomal l-OHP) were studied in mice. The anti-PEG IgM antibodies induced by the topical application of cosmetic products obviously accelerated the blood clearance of both PEGylated liposomal formulations. Moreover, in C26 tumor-bearing mice, the tumor growth suppressive effects of both Doxil and Liposomal l-OHP were significantly attenuated in the presence of anti-PEG IgM antibodies induced by the topical application of cosmetic products. These results confirm that the topical application of a cosmetic product containing PEG derivatives could produce preexisting anti-PEG antibodies that then affect the therapeutic efficacy of subsequent doses of PEGylated therapeutics.
Polyethylene Glycol (Peg)-Associated Immune Responses Triggered by Clinically Relevant Lipid Nanoparticles in Rats

Haiyang Wang,Yisha Wang,Changzheng Yuan,Xiao Xu,Wenbin Zhou,Yuhui Huang,Huan Lu,Yue Zheng,Gan Luo,Jia Shang,Meihua Sui

DOI: https://doi.org/10.1038/s41541-023-00766-z

2023-01-01

npj Vaccines

Abstract:With the large-scale vaccination of lipid nanoparticles (LNP)-based COVID-19 mRNA vaccines, elucidating the potential polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant LNP has become imminent. However, inconsistent findings were observed across very limited population-based studies. Herein we initiated a study using LNP carrier of Comirnaty ® as a representative, and simulated real-world clinical practice covering a series of time points and various doses correlated with approved LNP-delivered drugs in a rat model. We demonstrated the time- and dose-dependency of LNP-induced anti-PEG antibodies in rats. As a thymus-independent antigen, LNP unexpectedly induced isotype switch and immune memory, leading to rapid enhancement and longer lasting time of anti-PEG IgM and IgG upon re-injection in rats. Importantly, initial LNP injection accelerated the blood clearance of subsequent dosing in rats. These findings refine our understandings on LNP and possibly other PEG derivatives, and may promote optimization of related premarket guidelines and clinical protocols.
PEGylated liposomes: immunological responses

Marwa Mohamed,Amr S. Abu Lila,Taro Shimizu,Eman Alaaeldin,Amal Hussein,Hatem A. Sarhan,Janos Szebeni,Tatsuhiro Ishida

DOI: https://doi.org/10.1080/14686996.2019.1627174

IF: 7.821

2019-06-26

Science and Technology of Advanced Materials

Abstract:<span>A commonly held view is that nanocarriers conjugated to polyethylene glycol (PEG) are non-immunogenic. However, many studies have reported that unexpected immune responses have occurred against PEG-conjugated nanocarriers. One unanticipated response is the rapid clearance of PEGylated nanocarriers upon repeat administration, called the accelerated blood clearance (ABC) phenomenon. ABC involves the production of antibodies toward nanocarrier components, including PEG, which reduces the safety and effectiveness of encapsulated therapeutic agents. Another immune response is the hypersensitivity or infusion reaction referred to as complement (C) activation-related pseudoallergy (CARPA). Such immunogenicity and adverse reactivities of PEGylated nanocarriers may be of potential concern for the clinical use of PEGylated therapeutics. Accordingly, screening of the immunogenicity and CARPA reactogenicity of nanocarrier-based therapeutics should be a prerequisite before they can proceed into clinical studies. This review presents PEGylated liposomes, immunogenicity of PEG, the ABC phenomenon, C activation and lipid-induced CARPA from a toxicological point of view, and also addresses the factors that influence these adverse interactions with the immune system.<b>GRAPHICAL </b></span>

materials science, multidisciplinary
An Assay for Immunogenic Detection of Anti‐PEG Antibody

Xiang Zhu,Weizhe Luo,Donghui Zhang,Runhui Liu

DOI: https://doi.org/10.1002/cbic.202400316

IF: 3.2

2024-06-15

ChemBioChem

Abstract:With the increasing use of polyethylene glycol (PEG) based proteins and drug delivery systems, anti‐PEG antibodies have commonly been detected among the population, causing the accelerated blood clearance and hypersensitivity reactions, poses potential risks to the clinical efficacy and safety of PEGylated drugs. Therefore, vigilant monitoring of anti‐PEG antibodies is crucial for both research and clinical guidance regarding PEGylated drugs. The enzyme‐linked immunosorbent assay (ELISA) is a common method for detecting anti‐PEG antibodies. However, diverse coating methods, blocking solutions and washing solutions have been employed across different studies, and unsuitable use of Tween 20 as the surfactant even caused biased results. In this study, we established the optimal substrate coating conditions, and investigated the influence of various surfactants and blocking solutions on the detection accuracy. The findings revealed that incorporating 1% bovine serum albumin into the serum dilution in the absence of surfactants will result the credible outcomes of anti‐PEG antibody detection.

biochemistry & molecular biology,chemistry, medicinal
Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG

Gergely Tibor Kozma,Tamás Mészáros,Petra Berényi,Réka Facskó,Zsófia Patkó,Csaba Zs. Oláh,Adrienne Nagy,Tamás Gyula Fülöp,Kathryn Anne Glatter,Tamás Radovits,Béla Merkely,János Szebeni

DOI: https://doi.org/10.1016/j.vaccine.2023.06.009

IF: 4.169

2023-06-06

Vaccine

Abstract:A small fraction of recipients of polyethylene-glycol (PEG)-containing COVID-19 mRNA-LNP vaccines (Comirnaty and Spikevax) develop hypersensitivity reactions (HSRs) or anaphylaxis. A causal role of anti-PEG antibodies (Abs) has been proposed, but not yet proven in humans. We used ELISA for serial measurements of SARS-CoV-2 neutralizing Ab (anti-S) and anti-PEG IgG/IgM Ab levels before and after the first and subsequent booster vaccinations with mRNA-LNP vaccines in a total of 292 blood donors. The HSRs in 15 subjects were graded and correlated with anti-PEG IgG/IgM, just as the anti-S and anti-PEG Ab levels with each other. The impacts of gender, allergy, mastocytosis and use of cosmetics were also analyzed. Serial testing of two or more plasma samples showed substantial individual variation of anti-S Ab levels after repeated vaccinations, just as the levels of anti-PEG IgG and IgM, which were over baseline in 98-99 % of unvaccinated individuals. About 2-3% of subjects in the strongly left-skewed distribution had 15-30-fold higher values than the median, referred to as anti-PEG Ab supercarriers. Both vaccines caused significant rises of anti-PEG IgG/IgM with >10-fold rises in about ∼10% of Comirnaty, and all Spikevax recipients. The anti-PEG IgG and/or IgM levels in the 15 vaccine reactors (3 anaphylaxis) were significantly higher compared to nonreactors. Serial testing of plasma showed significant correlation between the booster injection-induced rises of anti-S and anti-PEG IgGs, suggesting dual anti-S and anti-PEG immunogenicity. Conclusions : The small percentage of people who have extreme levels of anti-PEG Ab in their blood may be at increased risk for HSRs/anaphylaxis to PEGylated vaccines and other PEGylated injectables. This risk might be further increased by the anti-PEG immunogenicity of these vaccines. To screen for anti-PEG Ab "supercarriers" may help preventing these adverse phenomena

immunology,medicine, research & experimental
The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation

Thai Thanh Hoang Thi,Emily H. Pilkington,Dai Hai Nguyen,Jung Seok Lee,Ki Dong Park,Nghia P. Truong

DOI: https://doi.org/10.3390/polym12020298

IF: 5

2020-02-02

Polymers

Abstract:Poly(ethylene glycol) (PEG) is widely used as a gold standard in bioconjugation and nanomedicine to prolong blood circulation time and improve drug efficacy. The conjugation of PEG to proteins, peptides, oligonucleotides (DNA, small interfering RNA (siRNA), microRNA (miRNA)) and nanoparticles is a well-established technique known as PEGylation, with PEGylated products have been using in clinics for the last few decades. However, it is increasingly recognized that treating patients with PEGylated drugs can lead to the formation of antibodies that specifically recognize and bind to PEG (i.e., anti-PEG antibodies). Anti-PEG antibodies are also found in patients who have never been treated with PEGylated drugs but have consumed products containing PEG. Consequently, treating patients who have acquired anti-PEG antibodies with PEGylated drugs results in accelerated blood clearance, low drug efficacy, hypersensitivity, and, in some cases, life-threatening side effects. In this succinct review, we collate recent literature to draw the attention of polymer chemists to the issue of PEG immunogenicity in drug delivery and bioconjugation, thereby highlighting the importance of developing alternative polymers to replace PEG. Several promising yet imperfect alternatives to PEG are also discussed. To achieve asatisfactory alternative, further joint efforts of polymer chemists and scientists in related fields are urgently needed to design, synthesize and evaluate new alternatives to PEG.

polymer science
Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine

Yi Ju,Wen Shi Lee,Hannah G Kelly,Emily H Pilkington,Kathleen M Wragg,Kanta Subbarao,Thi H.O. Nguyen,Louise C. Rowntree,Lilith F Allen,Katherine Bond,Deborah A Williamson,Nghia P Truong,Magdalena Plebanski,Katherine Kedzierska,Siddhartha Mahanty,Frank Caruso,Adam K Wheatley,Jennifer A Juno,Stephen J Kent

DOI: https://doi.org/10.1101/2022.01.08.22268953

2022-01-10

Abstract:Abstract Humans commonly have low level antibodies to poly(ethylene) glycol (PEG) due to environmental exposure. Lipid nanoparticle mRNA vaccines for SARS-CoV-2 contain small amounts of PEG but it is not known if PEG antibodies are enhanced by vaccination and if there are any consequences. We studied plasma from 55 people receiving the Comirnaty (Pfizer-BioNTech) mRNA vaccine for PEG-specific antibodies. Anti-PEG IgG was commonly detected prior to vaccination and was boosted a mean of 1.78-fold (range 0.68 to 16.6) by vaccination. Anti-PEG IgM increased 2.64-fold (0.76 to 12.84) following vaccination. PEG antibodies did not impact the neutralizing antibody response to vaccination. Pre-existing levels of anti-PEG IgM correlated with increased reactogenicity. A rise in PEG antibodies following vaccination was associated with an increase in the association of PEG-based nanoparticles to blood immune cells ex vivo. We conclude that low level PEG-specific antibodies can be modestly boosted by a lipid nanoparticle mRNA-vaccine and that PEG-specific antibodies are associated with higher reactogenicity. The longer-term clinical impact of the increase in PEG-specific antibodies induced by lipid nanoparticle mRNA-vaccines should be monitored. One-Sentence Summary A rise in PEG antibodies following mRNA lipid nanoparticle vaccination was associated with higher reactogenicity and PEG particle–leukocyte interactions.
Optimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin

Yue Li,Utibeabasi Ettah,Sarah Jacques,Hanmant Gaikwad,Andrew Monte,Layne Dylla,Saketh Guntupalli,S Moein Moghimi,Dmitri Simberg

DOI: https://doi.org/10.1021/acs.molpharmaceut.4c00278

2024-06-03

Abstract:There is considerable interest in quantifying anti-PEG antibodies, given their potential involvement in accelerated clearance, complement activation, neutralization, and acute reactions associated with drug delivery systems. Published and commercially available anti-PEG enzyme-linked immunosorbent assays (ELISAs) differ significantly in terms of reagents and conditions, which could be confusing to users who want to perform in-house measurements. Here, we optimize the ELISA protocol for specific detection of anti-PEG IgG and IgM in sera from healthy donors and in plasma from cancer patients administered with PEGylated liposomal doxorubicin. The criterion of specificity is the ability of free PEG or PEGylated liposomes to inhibit the ELISA signals. We found that coating high-binding plates with monoamine methoxy-PEG5000, as opposed to bovine serum albumin-PEG20000, and blocking with 1% milk, as opposed to albumin or lysozyme, significantly improve the specificity, with over 95% of the signal being blocked by competition. Despite inherent between-assay variability, setting the cutoff value of the optical density at the 80th percentile consistently identified the same subjects. Using the optimized assay, we longitudinally measured levels of anti-PEG IgG/IgM in cancer patients before and after the PEGylated liposomal doxorubicin chemotherapy cycle (1 month apart, three cycles total). Antibody titers did not show any increase but rather a decrease between treatment cycles, and up to 90% of antibodies was bound to the infused drug. This report is a step toward harmonizing anti-PEG assays in human subjects, emphasizing the cost-effectiveness and optimized specificity.
Clinical Impact of Antipolyethylene Glycol (PEG) Antibody in Hematological Patients Administered PEGylated-Granulocyte Colony-Stimulating Factor

Naoto Okada,Shimizu Taro,Hidenori Ando,Shingen Nakamura,Mitsuhiro Goda,Masahiro Abe,Takashi Kitahara,Tatsuhiro Ishida,Keisuke Ishizawa

DOI: https://doi.org/10.1002/cpdd.1225

Abstract:Polyethylene glycol (PEG) is a polymer covalently attached to proteins to improve their half-life and efficacy. We previously reported that the PEGylated granulocyte colony-stimulating factor (PEG-G-CSF) is immunogenic, which could adversely impact drug efficacy and safety in animal models. Here, we analyzed the relationship between anti-PEG antibody titers and the clinical impact of PEG-G-CSF in 19 hematological patients. A gradual decrease of anti-PEG antibody titers from baseline was observed after PEG-G-CSF administration. Of the 19 participants, 10 were assessed for noninfectious fever after the first administration of PEG-G-CSF and three experienced this reaction. The receiver operating characteristic curve revealed that the cut-off values of pretreated anti-PEG IgM and IgG titers for noninfectious fever were set at 5.0 and 96.6 U/mL, respectively. All patients who experienced noninfectious fever had anti-PEG antibody titers above this cut-off value (P = .033). An enzyme-linked immunosorbent assay revealed that some anti-PEG antibodies in patients with anti-PEG antibody titers above the cut-off value reacted with the PEGylated liposome. These results indicate the reactivity of the anti-PEG antibodies to PEGylated therapeutics observed in hematologic patients and the possibility of the relationship between high titers of anti-PEG antibodies and the development of adverse events after PEG-G-CSF administration.
Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines

Yi Ju,Juan Manuel Carreño,Viviana Simon,Kenneth Dawson,Florian Krammer,Stephen J. Kent

DOI: https://doi.org/10.1038/s41577-022-00825-x

IF: 108.555

2022-12-20

Nature Reviews Immunology

Abstract:The successful mRNA vaccines against COVID-19 contain polyethylene glycol (PEG) to stabilize the lipid nanoparticles. Recent data show that PEG-specific antibodies can be induced or boosted by mRNA vaccination. Further research is needed to study the potential links between PEG-specific antibodies, vaccine reactogenicity and enhanced clearance of other PEG-containing medicines.

immunology
Pre-existing anti-polyethylene glycol antibodies in pregnant women and newborns

Haiyang Wang,Yan Feng,Lin Zhang,Changzheng Yuan,Junyang Xue,Jicheng Li,Xiao Xu,Wenbin Zhou,Baohua Li,Yisha Wang,Gan Luo,Yue Zheng,Meihua Sui

DOI: https://doi.org/10.1101/2024.11.29.24317450

2024-12-04

Abstract:Importance: Pre-existing anti-polyethylene glycol (PEG) antibodies represent risk factors for reduced efficacy and increased adverse reactions in seropositive individuals receiving PEGylated drugs, but neither their sero-prevalence, nor levels nor potential influencing factors has been investigated in pregnant women or newborns. Objective: To parallelly determine the sero-prevalence and levels of pre-existing anti-PEG antibodies in pregnant women and their newborns, and to reveal their independent influencing factors. Design: Cross-sectional analysis using data of pregnant women and their newborns enrolled between May 2021 and May 2022. Setting: Pregnant women admitted for delivery at the Women's Hospital, Zhejiang University School of Medicine in China, were approached for enrollment. Participants: Participants included 256 pregnant women (volunteers) and corresponding 256 newborns. Major eligibility criteria for pregnant women included an age of 20 years or older, a singleton pregnancy, a full-term pregnancy, no history of unhealthy lifestyle , no previous contagious diseases and no other diseases upon enrollment. Exposures: Maternal and cord blood samples were collected and examined for pre-existing anti-PEG antibodies, along with questionnaire interviews, demographic and clinical data collections. Main Outcome and Measures: All blood samples underwent screening and quantification of anti-PEG antibodies. Sero-prevalence and levels of total pre-existing anti-PEG antibodies and each known isotype/subclass were determined in pregnant women and newborns. Influencing factors for sero-prevalence and/or levels of pre-existing anti-PEG antibodies in pregnant women and newborns were respectively revealed with in-depth statistical analysis. Results: The seropositivities of total anti-PEG antibodies, anti-PEG IgG1 and IgG2, anti-PEG IgM, and co-existence of anti-PEG IgM and IgG were 19.14%, 2.34%, 7.03%, 10.94% and 1.17%, respectively in pregnant women, and 5.47%, 2.73%, 2.73%, 0% and 0%, respectively in newborns. Anti-PEG IgG3, IgG4 and IgE were detectable in neither pregnant women nor newborns. Pregnant women with anti-PEG antibodies had a median (Range; IQR) anti-PEG IgG1, IgG2 and IgM concentrations of 273.88 ng/mL (183.74-513.90; 191.70-376.08), 748.35 ng/mL (75.54-2604.89; 159.09-1200.81) and 175.07 ng/mL (55.43-23649.14; 95.95-315.19), respectively. Newborns with anti-PEG antibodies had a median (Range; IQR) anti-PEG IgG1 and IgG2 concentrations of 207.92 ng/mL (120.40-1513.98; 133.97-524.58) and 336.52 ng/mL (100.24-1069.62; 275.80-527.07), respectively. This study revealed that maternal age, take out-food consumption, cosmetic use and occupation were influencing factors of prevalence and/or levels of maternal anti-PEG antibodies, and prevalence and/or levels of newborn anti-PEG antibodies were affected by maternal age, occupation and cosmetic use. Conclusions and Relevance: A proportion of pregnant women and newborns were found seropositive for pre-existing anti-PEG antibodies, raising efficacy and safety concerns over the use of PEGylated drugs in pregnant women and newborns. Several influencing factors on maternal and/or newborn pre-existing anti-PEG antibodies were discovered, which has provided valuable information for deeper understandings on the origins of PEG antigens and the induction of risky pre-existing anti-PEG antibodies.

Epidemiology
Development of anti-PEG IgG/IgM/IgE ELISA assays for profiling anti-PEG immunoglobulin response in PEG-sensitized individuals and patients with alpha-gal allergy

Zhongbo Li,Alice Ma,Ian Miller,Rachel Starnes,Anne Talkington,Cosby A Stone,Elizabeth J Phillips,Shailesh K Choudhary,Scott P Commins,Samuel K Lai,Cosby A. Stone,Elizabeth J. Phillips,Shailesh K. Choudhary,Scott P. Commins,Samuel K. Lai

DOI: https://doi.org/10.1016/j.jconrel.2024.01.003

IF: 11.467

2024-02-01

Journal of Controlled Release

Abstract:Polyethylene glycol (PEG) is frequently used in various protein and nanomedicine therapeutics. However, various studies have shown that select PEGylated therapeutics can induce production of anti-PEG antibodies (APA), potentially culminating in rapid clearance from the systemic circulation, loss of efficacy and possibly increased risks of allergic reactions. Although IgE is a frequent cause of immediate hypersensitivity reactions (IHR), the role of IgE APA in PEG-related IHR is not well understood, due in part to a lack of standardized assays for measuring IgE APA. Here, we developed a rigorous competitive ELISA method to measure the concentrations of various APA isotypes, including IgE, with picomolar sensitivities. In a small number of serum samples from patients with known PEG allergy, the assay allowed us to detect a strong correlation between IgG and IgE APA in individuals with history of allergic reactions to PEG or PEGylated drugs, but not between IgM and IgE APA. We detected appreciable levels of IgG and IgM APA in individuals with history of alpha-gal allergy, however, they were not elevated relative to those detected in other healthy controls, and we found no pre-existing IgE APA. While preliminary and should be further investigated, these results suggest that differences in the route and mechanism of PEG exposure may drive variability in APA response.

pharmacology & pharmacy,chemistry, multidisciplinary
Effects of PEG antibodies on in vivo performance of LNP-mRNA vaccines

Min Yang,Zengyu Zhang,Pengpeng Jin,Kuan Jiang,Yifei Xu,Feng Pan,Kaisong Tian,Zhou Yuan,Xiaohua Eric Liu,Jiaru Fu,Bin Wang,Huafang Yan,Changyou Zhan,Zui Zhang

DOI: https://doi.org/10.1016/j.ijpharm.2023.123695

2024-01-25

Abstract:Polyethylene glycol (PEG) plays important roles in stabilizing and lengthening circulation time of lipid nanoparticle (LNP) vaccines. Nowadays various levels of PEG antibodies have been detected in human blood, but the impact and mechanism of PEG antibodies on the in vivo performance of LNP vaccines has not been clarified thoroughly. By illustrating the distribution characteristics of PEG antibodies in human, the present study focused on the influence of PEG antibodies on the safety and efficacy of LNP-mRNA vaccine against COVID-19 in animal models. It was found that PEG antibodies led to shortened blood circulation duration, elevated accumulation and mRNA expression in liver and spleen, enhanced expression in macrophage and dendritic cells, while without affecting the production of anti-Spike protein antibodies of COVID-19 LNP vaccine. Noteworthily, PEG antibodies binding on the LNP vaccine increased probability of complement activation in animal as well as in human serum and led to lethal side effect in large dosage via intravenous injection of mice. Our data suggested that PEG antibodies in human was a risky factor of LNP-based vaccines for biosafety concerns but not efficacy.

Is body posture relevant for neonatal studies?

Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies

Hydroxy polyethylene glycol: a solution to evade human pre-existing anti-PEG antibodies for efficient delivery

Anti-PEG Antibodies: Current Situation and Countermeasures

PEGylated Liposomes for Diagnosis of Polyethylene Glycol Allergy

A singlicate immunogenicity method to detect anti-polyethylene glycol antibodies: pre- and post-dose of PEGylated therapies

To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives

The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?

Impact of Anti-PEG IgM Induced via the Topical Application of a Cosmetic Product Containing PEG Derivatives on the Antitumor Effects of PEGylated Liposomal Antitumor Drug Formulations in Mice

Polyethylene Glycol (Peg)-Associated Immune Responses Triggered by Clinically Relevant Lipid Nanoparticles in Rats

PEGylated liposomes: immunological responses

An Assay for Immunogenic Detection of Anti‐PEG Antibody

Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG

The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation

Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine

Optimized Enzyme-Linked Immunosorbent Assay for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin

Clinical Impact of Antipolyethylene Glycol (PEG) Antibody in Hematological Patients Administered PEGylated-Granulocyte Colony-Stimulating Factor

Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines

Pre-existing anti-polyethylene glycol antibodies in pregnant women and newborns

Development of anti-PEG IgG/IgM/IgE ELISA assays for profiling anti-PEG immunoglobulin response in PEG-sensitized individuals and patients with alpha-gal allergy

Effects of PEG antibodies on in vivo performance of LNP-mRNA vaccines